BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30819034)

  • 1. Evaluation of Intervention Impact on Health Inequality for Resource Allocation.
    Griffin S; Love-Koh J; Pennington B; Owen L
    Med Decis Making; 2019 Apr; 39(3):171-182. PubMed ID: 30819034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aggregate Distributional Cost-Effectiveness Analysis of Health Technologies.
    Love-Koh J; Cookson R; Gutacker N; Patton T; Griffin S
    Value Health; 2019 May; 22(5):518-526. PubMed ID: 31104729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How health inequalities accumulate and combine to affect treatment value: A distributional cost-effectiveness analysis of smoking cessation interventions.
    Love-Koh J; Pennington B; Owen L; Taylor M; Griffin S
    Soc Sci Med; 2020 Nov; 265():113339. PubMed ID: 33039733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distributional Cost-Effectiveness Analysis of Treatments for Non-Small Cell Lung Cancer: An Illustration of an Aggregate Analysis and its Key Drivers.
    Meunier A; Longworth L; Gomes M; Ramagopalan S; Garrison LP; Popat S
    Pharmacoeconomics; 2023 Aug; 41(8):1011-1025. PubMed ID: 37296369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Health Inequality Impact of Liquid Biopsy to Inform First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Distributional Cost-Effectiveness Analysis.
    Jansen JP; Ragavan MV; Chen C; Douglas MP; Phillips KA
    Value Health; 2023 Dec; 26(12):1697-1710. PubMed ID: 37741446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Equity and economic evaluation of system-level health interventions: A case study of Brazil's Family Health Program.
    Love-Koh J; Mirelman A; Suhrcke M
    Health Policy Plan; 2021 Apr; 36(3):229-238. PubMed ID: 33386400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Explicit incorporation of equity considerations into economic evaluation of public health interventions.
    Cookson R; Drummond M; Weatherly H
    Health Econ Policy Law; 2009 Apr; 4(Pt 2):231-45. PubMed ID: 19216834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uncertainty Analysis in Intervention Impact on Health Inequality for Resource Allocation Decisions.
    Yang F; Duarte A; Walker S; Griffin S
    Med Decis Making; 2021 Aug; 41(6):653-666. PubMed ID: 34098791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the potential return on investment of the proposed UK NHS diabetes prevention programme in different population subgroups: an economic evaluation.
    Thomas C; Sadler S; Breeze P; Squires H; Gillett M; Brennan A
    BMJ Open; 2017 Aug; 7(8):e014953. PubMed ID: 28827235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pharmacoeconomic approach to assessing the costs and benefits of air quality interventions that improve health: a case study.
    Lomas J; Schmitt L; Jones S; McGeorge M; Bates E; Holland M; Cooper D; Crowther R; Ashmore M; Rojas-Rueda D; Weatherly H; Richardson G; Bojke L
    BMJ Open; 2016 Jun; 6(6):e010686. PubMed ID: 27329439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using a survey to estimate health expectancy and quality-adjusted life expectancy to assess inequalities in health and quality of life.
    Collins B
    Value Health; 2013 Jun; 16(4):599-603. PubMed ID: 23796294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distributional cost effectiveness analysis of West Yorkshire low emission zone policies.
    Griffin S; Walker S; Sculpher M
    Health Econ; 2020 May; 29(5):567-579. PubMed ID: 32003147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ramaekers BLT; Wolff RF; Pouwels X; Oosterhoff M; Van Giessen A; Worthy G; Noake C; Armstrong N; Kleijnen J; Joore MA
    Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precision QALYs, Precisely Unjust.
    Fleck LM
    Camb Q Healthc Ethics; 2019 Jul; 28(3):439-449. PubMed ID: 31298190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of Funding Inpatient Treatments for COVID-19 on Health Equity in the United States: A Distributional Cost-Effectiveness Analysis.
    Kowal S; Ng CD; Schuldt R; Sheinson D; Cookson R
    Value Health; 2023 Feb; 26(2):216-225. PubMed ID: 36192293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distributional impact of the Malawian Essential Health Package.
    Arnold M; Nkhoma D; Griffin S
    Health Policy Plan; 2020 Jul; 35(6):646-656. PubMed ID: 32361730
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.